Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar, SBRT, and Envafolimab in Advanced GI Tumors
NCT06301828Phase 2Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of endostar, envafolimab in gastric cancer (GC), colorectal cancer (CRC), sponsored by Nanjing First Hospital. Started Feb 2024; status: recruiting.
02
Drugs
endostarenvafolimab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06301828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301828.